United States Securities and Exchange Commission
Washington, D.C. 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 5, 2021

KINDRED BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)
001-36225
(Commission File Number)
46-1160142
(I.R.S. Employer Identification No.)

1555 Bayshore Highway, Suite 200, Burlingame, California 94010
(Address of principal executive offices) (Zip Code)

(650) 701-7901
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.0001 par value</td>
<td>KIN</td>
<td>The NASDAQ Stock Market LLC</td>
</tr>
<tr>
<td>Preferred Stock Purchase Rights</td>
<td>KIN</td>
<td>The NASDAQ Stock Market LLC</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 5, 2021, the board of directors (the “Board”) of Kindred Biosciences, Inc. (“KindredBio”) appointed Nanxi Liu and Lyndon Lien, Ph.D., to serve as Class I directors of KindredBio, effective as of February 5, 2021, with each director having a term that expires at the 2023 annual meeting of stockholders. As a result of Ms. Liu and Dr. Lien's appointment, the authorized size of the Board was increased to eight members. There is no arrangement or understanding between Ms. Liu and any other person pursuant to which Ms. Liu was selected as a director. There is no arrangement or understanding between Dr. Lien and any other person pursuant to which Dr. Lien was selected as a director. There are no relationships between Ms. Liu and the Company or Dr. Lien and the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K. Each of Ms. Liu and Dr. Lien is an independent director in accordance with the listing requirements of The NASDAQ Stock Market. Ms. Liu and Dr. Lien's compensation will be consistent with the compensation of KindredBio’s other non-employee directors. Ms. Liu shall serve on the Board's Audit Committee, and Dr. Lien shall serve on the Board's Nominating and Corporate Governance Committee.

In accordance with the previous announcement by Ernest Mario, Ph.D. of his intention to retire as a director upon the appointment of a replacement director, as reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020, Dr. Mario retired from the Board on February 5, 2021. Dr. Mario will remain as an advisor to KindredBio for the remainder of 2021.

Lyndon Lien is Chief Executive Officer and co-founder of Qinotto, a biopharmaceutical company discovering and developing therapeutics for neurological diseases. Previously, he was Operating Partner at Pivotal bioVenture Partners, a life sciences venture capital firm. He was also Chief Executive Officer and co-founder of Balance Therapeutics, a rare cognition and sleep disorder biopharmaceutical company which he led from early preclinical development through Phase 2 clinical trials. Dr. Lien previously served in various strategy, business development, and operating roles at Elan, J&J, and McKinsey & Company. Dr. Lien received a PhD in Genetics and an AB from Harvard University, and an MBA from MIT Sloan School of Management.

Nanxi Liu is Chief Executive Officer and co-founder of Enplug, a digital display software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that enable vaccines and other biologics to be stored without refrigeration. Ms. Liu serves on the board of directors of CarParts.com, on the Board of Advisors for Covington Capital Management, and on the California Department of Motor Vehicles’ New Motor Vehicle Board. She received a BS in Business Administration and BA in Political Economy from UC Berkeley.

Item 7.01 Regulation FD Disclosure.

A copy of the press release dated February 9, 2021 announcing the appointments of Ms. Liu and Dr. Lien is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Act of 1933, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>104</td>
<td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td>
</tr>
</tbody>
</table>
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KINDRED BIOSCIENCES, INC.

Date: February 9, 2021

By: /s/ Richard Chin
Richard Chin, M.D.
Chief Executive Officer
Kindred Biosciences Announces Two New Appointments to Board of Directors

San Francisco, California (February 9, 2021) - Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its Board of Directors, effective February 5, 2021.

“We are very pleased to welcome Lyndon and Nanxi to our Board,” said Chief Executive Officer, Richard Chin, M.D. “With extensive investing, operating, and business development experience, Lyndon will bring valuable additional perspectives to KindredBio. Nanxi is a seasoned entrepreneur recognized by Forbes and Fortune magazines, who brings management and public board experience to KindredBio. We look forward to working with them as we advance our innovative biologics pipeline with a mission of saving and improving the lives of pets.”

Lyndon Lien is CEO and Co-Founder of Qinotto, a biopharmaceutical company discovering and developing therapeutics for neurological diseases. Previously, he was Operating Partner at Pivotal bioVenture Partners, a life sciences venture capital firm. He was also CEO and Co-Founder of Balance Therapeutics, a rare cognition and sleep disorder biopharmaceutical company which he led from early preclinical development through Phase 2 clinical trials. Dr. Lien previously served in various strategy, business development, and operating roles at Elan, J&J, and McKinsey. Dr. Lien received a PhD in Genetics and an AB from Harvard University, and an MBA from MIT Sloan School of Management.

Nanxi Liu is CEO and Co-Founder of Enplug, a digital display software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that enable vaccines and other biologics to be stored without refrigeration. Ms. Liu serves on the Board of CarParts.com, on the Board of Advisors for Covington Capital Management, and on the California Department of Motor Vehicles’ New Motor Vehicle Board. She received a BS in Business Administration and BA in Political Economy from UC Berkeley.

As previously planned, Ernest Mario, Ph.D. will retire from the Board of Directors. Dr. Mario will remain as an advisor to KindredBio for the duration of the year.

“I would like to thank Ernie for his leadership and service to the KindredBio Board. Having been involved with the company since the very beginning, Ernie has played a key role in our growth into one of the world’s leading veterinary biopharmaceutical companies. I consider Ernie to be a valuable mentor and I am glad that he will continue as an advisor for the rest of the year,” added Dr. Chin.

About Kindred Biosciences

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
For more information, visit: www.kindredbio.com

Contacts
For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438